Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial

Auteurs : Nawal Al Kaabi, MBBS; Yuntao Zhang, PhD; Shengli Xia, BSc; Yunkai Yang, MSc; Manaf M. Al Qahtani, MD; Najiba Abdulrazzaq, MBBS; Majed Al Nusair, MD; Mohamed Hassany, MD; Jaleela S. Jawad, MBBS; Jehad Abdalla, MBBS; Salah Eldin Hussein, MBBS; Shamma K. Al Mazrouei, MBBS; Maysoon Al Karam, MBBS; Xinguo Li, MSc; Xuqin Yang, MSc; Wei Wang, MSc; Bonan Lai, MSc; Wei Chen, MSc; Shihe Huang, PhD; Qian Wang, MSc; Tian Yang, BSc; Yang Liu, MSc; Rui Ma, MSc; Zaidoon M. Hussain, MD; Tehmina Khan, MD; Mohammed Saifuddin Fasihuddin, BSc; Wangyang You, BSc; Zhiqiang Xie, MSc; Yuxiu Zhao, MSc; Zhiwei Jiang, PhD; Guoqing Zhao, PhD; Yanbo Zhang, MSc; Sally Mahmoud, PhD; Islam ElTantawy, BSc; Peng Xiao, MSc; Ashish Koshy, MSc; Walid Abbas Zaher, PhD; Hui Wang, BSc; Kai Duan, PhD; An Pan, PhD; Xiaoming Yang, MD

Revue : The Journal of the American Medical Association (JAMA)

Date : publication en ligne le 26 mai 2021

This prespecified interim analysis of a randomized clinical trial included 40 382 participants who received at least 1 dose of a 2-dose inactivated vaccine series developed from either SARS-CoV-2 WIV04 (5 µg/dose) or HB02 (4 µg/dose) strains or an aluminum hydroxide–only control, with a primary end point of the incidence of symptomatic COVID-19 at least 14 days after the second injection. The efficacy for the 2 vaccines, compared with an aluminum hydroxide–only control, was 72.8% in the WIV04 group and 78.1% in the HB02 group; both comparisons were statistically significant.

Source : Nawal Al Kaabi, Yuntao Zhang, Shengli Xia [et al.], “Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial”, Journal of the American Medical Association (JAMA), publication en ligne le 26/05/2021. DOI : 10.1001/jama.2021.8565 (consulté le 27/05/2021).

Photo “à la une” : Figure 3. Common Adverse Reactions and Grades Within 7 Days After 2 Doses in the Safety Analysis Set © DR

Vous aimerez aussi...

Laisser un commentaire

Votre adresse e-mail ne sera pas publiée.

Ce site utilise Akismet pour réduire les indésirables. En savoir plus sur comment les données de vos commentaires sont utilisées.

Rechercher dans OpenEdition Search

Vous allez être redirigé vers OpenEdition Search